A biotech hedge fund births a new immunology company — Live Feedhttps://www.live-feeds.com/feed/a-biotech-hedge-fund-births-a-new-immunology-companyContinuously updated, source-cited coverage. North Immunology goes public via merger with Aethlon Medicalhttps://www.live-feeds.com/feed/a-biotech-hedge-fund-births-a-new-immunology-companyhttps://www.live-feeds.com/feed/a-biotech-hedge-fund-births-a-new-immunology-company#u75725Sat, 19 Sep 2026 04:31:20 +0000North Immunology is entering the public market through a reverse merger with Aethlon Medical. The combined entity aims to advance a novel IL-13 x IL-18 bispecific antibody designed to treat atopic dermatitis. The drug is currently moving toward clinical trials. This venture was initiated by a biotech hedge fund to establish the immunology company.Why it mattersAtopic dermatitis, commonly known as eczema, requires targeted immunotherapies to manage inflammation. A reverse merger allows a private company to bypass the traditional IPO process to gain public listing and capital.What is confirmedNo